Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;126(4):481-516.
doi: 10.1007/s00702-018-1957-2. Epub 2018 Dec 19.

Dopamine and addiction: what have we learned from 40 years of research

Affiliations
Free article
Review

Dopamine and addiction: what have we learned from 40 years of research

Marcello Solinas et al. J Neural Transm (Vienna). 2019 Apr.
Free article

Abstract

Among the neurotransmitters involved in addiction, dopamine (DA) is clearly the best known. The critical role of DA in addiction is supported by converging evidence that has been accumulated in the last 40 years. In the present review, first we describe the dopaminergic system in terms of connectivity, functioning and involvement in reward processes. Second, we describe the functional, structural, and molecular changes induced by drugs within the DA system in terms of neuronal activity, synaptic plasticity and transcriptional and molecular adaptations. Third, we describe how genetic mouse models have helped characterizing the role of DA in addiction. Fourth, we describe the involvement of the DA system in the vulnerability to addiction and the interesting case of addiction DA replacement therapy in Parkinson's disease. Finally, we describe how the DA system has been targeted to treat patients suffering from addiction and the result obtained in clinical settings and we discuss how these different lines of evidence have been instrumental in shaping our understanding of the physiopathology of drug addiction.

Keywords: Neuroplasticity; Reward; Striatum; Substance abuse; Substantia nigra; Treatment; VTA.

PubMed Disclaimer

References

    1. J Pharmacol Exp Ther. 1994 Dec;271(3):1391-8 - PubMed
    1. Synapse. 1997 May;26(1):55-61 - PubMed
    1. Neuroscience. 1980;5(1):63-72 - PubMed
    1. Pharmacol Biochem Behav. 2003 May;75(2):373-9 - PubMed
    1. Expert Opin Investig Drugs. 2013 Dec;22(12):1549-68 - PubMed

MeSH terms